论文部分内容阅读
目的:比较吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的缓解率、一年生存率与毒性反应。方法:检索Pubmed数据库和CHKD数据库,纳入随机对照试验,用专用软件Review Manager version 4.2.2进行系统评价。结果:共有8个研究1741例患者纳入系统评价,吉西他滨+顺铂方案与长春瑞滨+顺铂方案在总缓解率和一年生存率上无区别,吉西他滨+顺铂方案中性粒细胞减少发生率低于长春瑞滨+顺铂方案,血小板减少发生率高于长春瑞滨+顺铂方案,恶心呕吐发生率与神经系统反应两者差异无统计学意义。结论:在晚期非小细胞肺癌治疗中,吉西他滨联合顺铂与长春瑞滨联合顺铂疗效相似,在毒性反应方面各有利弊,应结合患者具体情况,选择对患者生活质量影响较小的方案。
OBJECTIVE: To compare the response rates of gemcitabine, vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC), one-year survival rate and toxicity. Methods: The Pubmed database and the CHKD database were searched and included in a randomized controlled trial. The review was performed using a reviewer version 4.2.2. Results: A total of 8 studies included 1741 patients included in the systematic review. There was no difference between the gemcitabine + cisplatin regimen and the vinorelbine + cisplatin regimen in overall remission rate and one-year survival rate. Neutropenia occurred in the gemcitabine + cisplatin regimen The rate of thrombocytopenia was lower than that of vinorelbine + cisplatin. The incidence of thrombocytopenia was higher than that of vinorelbine plus cisplatin. There was no significant difference between the two groups in incidence of nausea and vomiting and nervous system reaction. Conclusion: In the treatment of advanced non-small cell lung cancer, gemcitabine combined with cisplatin and vinorelbine combined with cisplatin have similar curative effects, and have their own advantages and disadvantages in toxicity. Patients should be selected according to the specific conditions of the patients.